{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes&page=22",
    "query": {
      "condition": "Type 2 Diabetes",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 3775,
    "total_pages": 378,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T18:36:39.940Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00398853",
      "title": "Effect of Chromium Picolinate on Insulin Sensitivity in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "chromium picolinate 1000 mcg daily vs placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2003-10",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2016-04-08",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00398853"
    },
    {
      "nct_id": "NCT00162305",
      "title": "A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BMS-512148",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 47,
      "start_date": "2005-04",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 5,
      "location_summary": "Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00162305"
    },
    {
      "nct_id": "NCT00185601",
      "title": "Internet Diabetes Self-Management Workshop",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Internet Diabetes Self-Management Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 761,
      "start_date": "2006-02",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2013-04-19",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00185601"
    },
    {
      "nct_id": "NCT02787551",
      "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide fixed ratio combination",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "exenatide extended-release",
          "type": "DRUG"
        },
        {
          "name": "albiglutide",
          "type": "DRUG"
        },
        {
          "name": "dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2016-07-06",
      "completion_date": "2018-11-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02787551"
    },
    {
      "nct_id": "NCT02320253",
      "title": "REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "In Person Group (IP)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Telephone Conference Call Group (TCC)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Medical Nutrition Therapy (MNT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2014-11",
      "completion_date": "2021-07",
      "has_results": true,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts • Charlestown, Massachusetts • Chelsea, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        },
        {
          "city": "Chelsea",
          "state": "Massachusetts"
        },
        {
          "city": "Revere",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02320253"
    },
    {
      "nct_id": "NCT01807377",
      "title": "Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "PF-05175157",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-04",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2013-09-17",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01807377"
    },
    {
      "nct_id": "NCT06902077",
      "title": "A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "low carb diet",
          "type": "BEHAVIORAL"
        },
        {
          "name": "diabetic diet",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-11-25",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-08",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06902077"
    },
    {
      "nct_id": "NCT00727857",
      "title": "Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Pioglitazone and metformin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2007-06",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-07-29",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00727857"
    },
    {
      "nct_id": "NCT01952145",
      "title": "A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec/liraglutide",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 557,
      "start_date": "2013-09-20",
      "completion_date": "2014-11-04",
      "has_results": true,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 31,
      "location_summary": "Fresno, California • Los Alamitos, California • Palm Springs, California + 26 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952145"
    },
    {
      "nct_id": "NCT00952445",
      "title": "A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II"
      ],
      "interventions": [
        {
          "name": "T0903131 Besylate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InteKrin Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 70,
      "start_date": "2003-12",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2022-10-19",
      "last_synced_at": "2026-10-24T18:36:39.940Z",
      "location_count": 21,
      "location_summary": "La Jolla, California • Los Angeles, California • Santa Ana, California + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00952445"
    }
  ]
}